Please assess the completion status of the following clinical trial:

Trial Title: SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of axial spondylarthritis (axSpA, either ankylosing spondylitis or non radiographic axial spondylarthritis) according to ASAS axSpA classification criteria~* patients with back pain for at least 3 months and age of onset less than 45 years~* Active axSpA as assessed by total BASDAI score of at least 4 at Baseline.~* Spinal pain numeric rating scale score of more than 4 at Baseline.~* inadequate response to or failure to respond to at least 2 different NSAIDs at the highest recommended dose for at least 4 weeks in total prior to randomization~Key Exclusion Criteria:~* Chest X-ray or MRI with evidence of ongoing infectious or malignant process~* Patients previously treated with any biological immunomodulating agents, except those targeting tumor necrosis factor alpha.~* Patients who have been exposed to more than one anti-tumor necrosis factor alpha agent.~* Active ongoing inflammatory diseases other than axial spondyloarthritis~* Other ongoing mechanical diseases affecting the spine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 150 mg (Group A) (Type: EXPERIMENTAL): Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4
- Placebo (Group B) (Type: PLACEBO_COMPARATOR): Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4
- Arm A1 (Type: ACTIVE_COMPARATOR): Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
- Arm A2 (Type: ACTIVE_COMPARATOR): Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
- Arm A3 (Type: ACTIVE_COMPARATOR): Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
- Arm B1 (Type: ACTIVE_COMPARATOR): Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
- Arm B2 (Type: ACTIVE_COMPARATOR): Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20

Based on this trial design, predict the completion outcome and termination type (if applicable).